Fitzpatrick A P, Lee R J, Epstein L M, Lesh M D, Eisenberg S, Sheinman M M
Manchester Heart Centre, Manchester Royal Infirmary.
Heart. 1996 Nov;76(5):406-11. doi: 10.1136/hrt.76.5.406.
To define the value of tilt testing and hte additional yield of drug provocation over prolonged baseline tilt in different patient subgroups. (Many different protocols are in use for head-up tilt testing in heterogeneous groups of patients. Not all patients in reported series have recurrent syncope, and there is often a wide age range and a variable incidence of structural heart disease.)
In a prospective study, baseline 60 degrees head-up tilt testing was undertaken for 45 minutes, initially without drug provocation. Patients who remained symptom free were given intravenous isoprenaline (isoproterenol) and further tilting or edrophonium (10 mg bolus) during tilt, in an order determined randomly before the start of the test. If they were symptom free after the first drug, they were given the other drug. A positive test was recorded when syncope or pre-syncope occurred with a rapid fall (> 30%) in blood pressure. The impact on tilt result of the type of symptoms, presence of significant structural heart disease (SHD), presence of a non-cardiovascular cause of sudden diminished consciousness (SDC), and age was then assessed by subgroup analysis.
145 patients (73 female, mean age 51 (25), range 8-94) with one or more episodes of pre-syncope or syncope.
39 patients (27%, 21 female, age 49 (25) years) had positive tests and 106 (73%, 52 female, age 52 (25) years) negative tests. 27 (69%) had a positive test during baseline tilt at 20.5 (10.8) minutes, five (13%) with isoprenaline infusion, and seven (18%) with edrophonium bolus. Patients with recurrent syncope rather than single syncopal episodes or single or recurrent pre-syncope were more likely to have a positive tilt test (41% v 17%, P < 0.005) and patients with SHD or SDC (69/14 patients) were much less likely than patients without (16% v 42%, P < 0.0001). The yield of positive tests was similar if patients were below (26%) or above (27%) the mean age (50 years). When multiple factors were combined, the yield ranged from 0% for 21 patients under 50 years with SHD or SDC and without recurrent syncope to 73% in 11 patients over 50 years with recurrent syncope and no SHD or SDC. The additional yield in subgroups over 45 minute baseline tilt (70 (11)%) of isoprenaline (13 (10)%) was similar to that of edrophonium (17 (8)%, P = NS), but six (50% of those who were drug positive) patients required a second drug to produce a positive result (two with isoprenaline second, four with edrophonium second).
Head-up tilt testing in a heterogeneous population has a low yield. Simple clinical characteristics define the type of patient who is likely to have a positive tilt test and the patient who is not and in whom other investigations should receive priority. The great majority of positive tests will occur during prolonged baseline testing if this is used. Isoprenaline and edrophonium produced similar additional yields of positive tests.
确定倾斜试验的价值以及在不同患者亚组中,与延长的基础倾斜相比,药物激发试验的额外诊断价值。(在不同类型的患者群体中,有许多不同的方案用于头高位倾斜试验。报告系列中的并非所有患者都有复发性晕厥,而且患者年龄范围通常较广,结构性心脏病的发生率也各不相同。)
在一项前瞻性研究中,进行了45分钟的60度头高位基础倾斜试验,最初不进行药物激发。无症状的患者在试验开始前随机确定给药顺序,先静脉注射异丙肾上腺素(异丙基肾上腺素),然后在倾斜过程中再次倾斜或注射依酚氯铵(10毫克推注)。如果在首次用药后无症状,则给予另一种药物。当出现晕厥或先兆晕厥且血压快速下降(>30%)时记录为阳性试验。然后通过亚组分析评估症状类型、显著结构性心脏病(SHD)的存在、非心血管性意识突然减退(SDC)的存在以及年龄对倾斜试验结果的影响。
145例有一次或多次先兆晕厥或晕厥发作的患者(73例女性,平均年龄51(25)岁,范围8 - 94岁)。
39例患者(27%,21例女性,年龄49(25)岁)试验结果为阳性,106例(73%,52例女性,年龄52(25)岁)为阴性。27例(69%)在基础倾斜20.5(10.8)分钟时试验结果为阳性,5例(13%)在输注异丙肾上腺素期间为阳性,7例(18%)在注射依酚氯铵推注后为阳性。有复发性晕厥而非单次晕厥发作或单次或复发性先兆晕厥的患者更有可能倾斜试验结果为阳性(41%对17%,P < 0.005),有SHD或SDC的患者(69/14例患者)比无此类情况的患者试验结果为阳性的可能性小得多(16%对42%,P < 0.0001)。如果患者年龄低于(26%)或高于(27%)平均年龄(50岁),阳性试验的诊断价值相似。当多种因素综合考虑时,阳性试验的诊断价值范围从21例年龄小于五十岁、有SHD或SDC且无复发性晕厥患者的0%到11例年龄大于五十岁、有复发性晕厥且无SHD或SDC患者的73%。与依酚氯铵(17(8)%,P = 无显著性差异)相比,异丙肾上腺素在45分钟基础倾斜(70(11)%)基础上的额外诊断价值(13(10)%)相似,但6例(药物激发试验阳性患者中的50%)患者需要第二种药物才能产生阳性结果(2例第二次使用异丙肾上腺素,4例第二次使用依酚氯铵)。
在异质性人群中进行头高位倾斜试验的诊断价值较低。简单的临床特征可确定可能倾斜试验结果为阳性的患者类型以及不会出现阳性结果的患者类型,对于后者应优先进行其他检查。如果采用延长的基础试验,绝大多数阳性试验将在该过程中出现。异丙肾上腺素和依酚氯铵产生的阳性试验额外诊断价值相似。